Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report.
Article Type: Brief article
Subject: Medicare (Information management)
Medicare (Usage)
Erythropoietin (Usage)
Erythropoietin (Health aspects)
Anemia (Risk factors)
Author: Fischer, Michael J.
Pub Date: 12/30/2010
Publication: Name: Journal of Rehabilitation Research & Development Publisher: Department of Veterans Affairs Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2010 Department of Veterans Affairs ISSN: 0748-7711
Issue: Date: Dec 30, 2010 Source Volume: 47 Source Issue: 8
Topic: Event Code: 260 General services Computer Subject: Company systems management
Geographic: Geographic Scope: United States Geographic Code: 1USA United States
Accession Number: 246450390
Full Text: Veterans are at high risk for developing kidney disease, and those who develop the disease have extremely high morbidity and mortality rates. Anemia is a frequent complication of kidney disease and leads to poor health. To treat anemia successfully in veterans, physicians administer erythropoiesis-stimulating agents (ESAs). Much of the prior research investigating the relationship between ESAs, anemia, and kidney disease is based on information from Medicare's Medical Evidence Report (Form 2728). Before this study, the accuracy of the information on Form 2728 was not known. This study found significant errors in ESA information reported on Form 2728, which could have led to biased findings and misunderstandings in prior research. Recognition of these shortcomings of Form 2728 will benefit researchers because they will be able to conduct better studies of this matter in the future.

Michael J. Fischer, MD, MSPH, et al.
Gale Copyright: Copyright 2010 Gale, Cengage Learning. All rights reserved.